【文獻標題】Alogliptin prevents diastolic dysfunction and preserves left ventricular mitochondrial function in diabetic rabbits
【作者】Xiaowei Zhang,Zhiwei Zhang,Yajuan Yang,et.al
【作者單位】天津醫科大學第二醫院(Second Hospital of Tianjin Medical University)
【文獻中引用產品】
兔胰高血糖素(Glucagon)ELISA試劑盒
兔8羥基脫氧鳥苷(8-OHdG)ELISA試劑盒
【關鍵詞】Dipeptidyl peptidase-4 inhibitors, Diabetic cardiomyopathy, Diabetes mellitus, Mitochondrial function, Mitochondrial biogenesis
【DOI】doi.org/10.1186/s12933-018-0803-z
【影響因子(IF)】9.5
【出版期刊】《BMC BIOLOGY》
【產品原文引用】
Serum biochemical, infammatory oxidative stress measurements
Blood samples collected were used for serum biochemical examination, including fasting glucose, total cholesterol, triglyceride, low-density lipoprotein cholesterol (LDL-c), high density lipoprotein cholesterol (HDL-c) and creatinine level by full automatic biochemical analyzer. Fasting insulin and GLP-1 level were assessed using Rabbit Insulin ELISA Kit (Wuhan Huamei Biological Engineering Co., Ltd, Hubei Province, China) and Rabbit Glucagon Like Peptide-1 ELISA Kit (Shanghai Huding Biological Technology Co., Shanghai, China) according to the manufacturer’s instructions respectively. Serum oxidative stress related markers Lipid Peroxidation Malondialdehyde (MDA) and 8-hydroxy-2 deoxyguanosine (8-OHdG) were assessed by MDA Assay Kit (Nanjing Jianchen Bioengineering Institute, Jiangsu Province, China) and Rabbit 8-OHdG ELISA Kit (Shanghai Huding Biological Technology Co., Shanghai, China). Serum antioxidant enzyme superoxide Jianchen Bioengineering Institute, Jiangsu Province, China). And the infammation maker high-sensitivity C-reactive protein (hs-CRP) level was detected using Rabbit hs-CRP ELISA KIT (Wuhan Huamei Biological Engineering Co., Ltd, Hubei Province, China).
完整版PDF文獻請咨詢在線客服或者dian話聯系我司業務員!
更多公司福利請關注“上海滬鼎”VX公眾號!
相關產品
免責聲明
- 凡本網注明“來源:化工儀器網”的所有作品,均為浙江興旺寶明通網絡有限公司-化工儀器網合法擁有版權或有權使用的作品,未經本網授權不得轉載、摘編或利用其它方式使用上述作品。已經本網授權使用作品的,應在授權范圍內使用,并注明“來源:化工儀器網”。違反上述聲明者,本網將追究其相關法律責任。
- 本網轉載并注明自其他來源(非化工儀器網)的作品,目的在于傳遞更多信息,并不代表本網贊同其觀點和對其真實性負責,不承擔此類作品侵權行為的直接責任及連帶責任。其他媒體、網站或個人從本網轉載時,必須保留本網注明的作品第一來源,并自負版權等法律責任。
- 如涉及作品內容、版權等問題,請在作品發表之日起一周內與本網聯系,否則視為放棄相關權利。